1 Life Sciences Industry in Canada Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015
2 Life Sciences in Canada Canadian life sciences sector is an important contributor to Canada's innovation economy, engaging in creating the medical innovations that will improve health-care delivery and patient care in Canada and abroad. Research, development and manufacturing continuum SMEs developing diagnostics, biopharmaceuticals, pharmaceuticals and medical devices MNCs with research, development and manufacturing operations Contract services provide research and development, clinical trials and manufacturing Canada's world-class health research institutions and research networks are integral partners in research and knowledge translation.
3 Life Sciences in Canada A Key Player in the Global Pharmaceuticals Industry Home to the world s largest pharmaceutical companies, with several of these locating R&D and manufacturing facilities here, Canada offers a dynamic environment with first-rate academic institutions, innovative research networks, a highly skilled workforce, and many partnership opportunities. A Leader in the Medical Devices Industry Canada s medical devices sector is highly diversified, R&D intensive, technology-based and export-oriented. Purchasers include hospitals, physician s offices, laboratories, clinics and patients. Canadian medical devices firms spend, on average, 12 percent of yearly revenues on development, design and commercialization. A Major Opportunity for Growth in the Health IT Vertical Industry Healthcare spending in Canada reached $211 billion in 2013, representing about 11.2% of GDP. A key focus of policy makers has been to harness technology to enhance efficiencies within the healthcare system, with $10 billion to $12 billion to be invested in Health IT infrastructure across the country in the next 8-10 years. A Top-Notch Location for the Conduct of Clinical Trials Canada s ethnically diverse population, broad and universal healthcare coverage, world-leading universities, hospitals and health research centres staffed with highly qualified investigators in all major therapeutic areas make Canada a top quality location for conducting clinical trials.
4 Diversified, Vibrant and Growing Market for Pharmas In 2013, the sector s manufacturing segment employed 27,000 people in 490 establishments. Also, Canadian companies spent close to $900 million in 2012 on R&D activities in the pharmaceutical sector. From 2001 to 2013, total pharmaceutical sales in Canada almost doubled to $21.6 billion, with 89 percent sold to retail and 11 percent to hospitals. Governments account for 42 percent of drug expenditures while private payers cover the remainder. Brand-name products comprise 76 percent of Canadian sales and 37 percent of prescriptions, and generics account for the rest. Pharmaceutical sales in Canada represent 2.5 percent of the global industry, making Canada the eighth-largest market in the world. The Canadian pharmaceutical sector also has a growing presence in international markets; between 2001 and 2012, the value of its exports and imports increased by 136 and 93 percent, respectively. More than half of Canadian production, worth approximately $5.2 billion, is exported, primarily to the United States.
5 Key Strengths in the Pharmaceutical Industry A pharmaceutical sector that spans the industry s spectrum, operating at all levels of the value chain, from basic R&D and innovation to drug product development and contract services Several health-research networks covering all key therapeutic areas and that are ever-more commercially oriented, providing value and expertise to firms securing partnerships with them A total of 200 contract research organizations and contract manufacturing organizations (CROs and CMOs) serving both Canadian and international clients Perfectly suited to the current climate of patent expirations, and the demand for new licensing prospects, partnerships and alternative forms of investment
6 Pharmaceutical Market Access Innovative medicines, generics and over the counter drug products are developed and manufactured in Canada Health Canada regulates the pharmaceutical industry (Food & Drug Act) The review of a drug takes an average of 18 months from the time that a sponsor submits a New Drug Submission until the TPD makes a marketing decision CADTH Common Drug Review reviews new drugs and provides formulary listing recommendations to all publiclyfunded drug benefit plans in Canada except Quebec Payers for prescription drugs Public payers (governments, hospitals) 44% Private sector (insurance companies) 38% Consumer (out-of-pocket) 18%
7 Medical Devices in Canada Canada s Medical Devices Industry is dynamic, export-oriented Canada s medical devices sector encompasses about 1,500 firms employing 35,000 people and exported over $1.9 billion worth of medical devices in Demographic trends, developments in science and engineering, and changes in care delivery are contributing to the sector s growth. Canada s medical devices sector is highly diversified, R&D intensive, technology-based and export-oriented. The Medical Devices market is integrated and lucrative In 2012, the global market for medical devices was valued at US$327.7 billion, with the share of the United States spending assessed at US$188.9 billion on medical devices. Canada s medical devices market was estimated at $6.8 billion, ranking it ninth globally. Key business segments of sales in Canada are diagnostic apparatus, consumables, patient aids, orthopaedics and prosthetics. Thanks to North American Free Trade Agreement (NAFTA), Canadian companies have tariff-free access to the U.S. market for medical devices.
8 Medical Devices in Canada Canada s Key Strengths in the Medical Devices Industry Diversified, export-oriented and innovative sector Several specialised networks of world-class researchers Active in the areas of biotechnology, advanced materials, aerospace, microelectronics, telecommunications, software and informatics Examples of leading edge medical device products developed and/or manufactured by Canadian companies: The Neovasc Reducer and Tiara (Vancouver, British Columbia), Novadaq Technologies imaging systems (Toronto, Ontario) Medtronic CryoCath catheter-based products (Montréal, Quebec), Imaging Dynamics digitalradiography-imaging system (Calgary, Alberta), Epocal handheld blood-analysis systems (Ottawa, Ontario) Baylis Medical radio-frequency puncture systems (Montréal, Quebec and Toronto, Ontario) and MedMira point-of-care diagnostics (Halifax, Nova Scotia)
9 Medical Devices Market Access in Canada Health Canada - Medical Device Regulations (Food & Drug Act) Covers the manufacturing, advertising for sale and sale of a medical device Includes importation of a medical device for sale or use on individuals, other than importation for personal use Progressive licensing with Class I, II, III, & IV devices based on risk of harm Class II, III & IV requires ISO Quality Management System certificate Health Canada regulatory review standards: 90 days for Class IV 75 days for Class III 15 days for Class II Governments are payers and hospitals are the major buyers at 80% of market Fragmented path to market
10 Canada s Health IT Sector Canada s Health IT industry enjoys broad public and private support Health IT accounts for about 2% ($4.2 billion) of all healthcare ($211 billion) spend per year. The overall North American Health IT market is forecasted to grow at a compound annual growth rate of 7.4 percent to reach $31.3 billion by 2017 from $21.9 billion in 2012, according to Research and Markets North American Healthcare IT Market Report Canada s Federal and Provincial governments are committed to leveraging ICT technologies to make Canada s healthcare system a high quality and affordable model of healthcare delivery, with fewer inefficiencies. Out of this commitment evolved the Canada Health Infoway group ( Infoway ), an organization mandated to define and coordinate the implementation of Canada s national Health IT initiatives. As of December 31, 2013 the Federal government had provided over CAD $2 Billion to Infoway for the funding of 294 Health IT-related projects.
11 Strengths of the Health IT Sector Main factors behind the strength of Canada s Health IT industry The three major factors likely to propel the Canadian Health IT market are its publicly funded health structure, the prominent role played by Canada Health Infoway, and growing pressures to obtain a better return for every dollar spent on healthcare, due to an aging population and the rise in incidences of chronic diseases. The growing opportunity in the Health IT market has already attracted major global multinationals like Microsoft, Agfa, Siemens and Honeywell into offering Health IT solutions in Canada, in areas such as EMRs, doctor office s IT solutions, and patients mobile access. The talent pool is ready and available: several educational programs dedicated to the field of Health IT are offered in Canada, and Health Informatics educational programs continue to be a sought after field. Solutions provided by Canadian Health IT vendors cover several technology areas including Picture Archiving and Communication Systems, Drug Information Systems, Electronic Health Records, Electronic Medical Records, Clinical Information Systems, and Wireless & Communications.
12 Quality of Clinical Research Clinical Trials in Canada The quality of clinical research in Canada is outstanding, thanks to unique assets stemming from its demographics, health care system and labour force. These assets include Canada s ethnically diverse population, broad and universal healthcare coverage, world-leading universities, hospitals and health research centres staffed with highly qualified investigators who have expertise in all major therapeutic areas. The recently launched Canadian Clinical Trials Coordination center (CCTCC) is an organization whose main priority is to build on and further reinforce Canada s competitive clinical trials environment. Efficiency of Clinical Research Health Canada has decreased its target for the review of clinical trial applications to 30 days, and consistently meets this new goal. Setup times in Canada are among the best in the world, and it currently takes three months on average to set up a clinical trial here. KPMG s Competitive Alternatives report of 2014 gives Canada a 15.9 points advantage on competitiveness over the U.S. for the annual operational costs related to clinical trials administration centers.
Opportunities and Trends in Investing in the Health Sector Overview This section provides an overview for financial institutions interested in learning more about the health sector. It defines the private
The International Healthcare Sector Opportunities for Virginia Defense Companies Virginia Economic Development Partnership Summary of Report This report is focused on five international healthcare markets:
Business Process Outsourcing Accenture Learning BPO Services Helping talent-powered organizations drive growth, efficiency and high performance through learning With its learning BPO services offering,
Annual Reports and Financial Statements 2010 Reed Elsevier is a world leading provider of professional information solutions in the Science, Medical, Risk, Legal and Business sectors. Our customers use
International Profiles of Health Care Systems Australia, Canada, Denmark, England, France, Germany, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States The Commonwealth
Policy Statement on Foreign Direct Investment in Ireland July 2014 Foreword Foreign Direct Investment (FDI) has played a significant role in advancing Ireland s economic development over the past decades
Ministry of Training, Colleges and Universitites The etextbook Initiative Strategic Mandate Agreement (SMA) DRAFT Proposal A submission to begin the SMA discussion process From: Dr. Kent MacDonald, President
IMPROVING REHABILITATION SERVICES FOR THE PEOPLE OF BRITISH COLUMBIA Submitted by the Physician Working Group on Rehabilitation Services July 13, 2007 Page 1 Physician Working Group on Rehabilitation Services
Working Paper 20 April 2014 WP 20 BUILDING BETTER HEALTH CARE Policy opportunities for Ontario Institute for Competitiveness & Prosperity The Institute for Competitiveness & Prosperity is an independent
Annual Reports and Financial Statements Reed Elsevier is a world leading provider of professional information solutions. We leverage deep customer understanding to deliver demonstrably improved outcomes
Delivering our Green Potential Government Policy Statement on Growth and Employment in the Green Economy Government of Ireland, 2012 Contents Foreword by An Taoiseach, Enda Kenny, T.D. 1 Key Messages 2
013 Co-operators General Insurance Company Annual Report >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Mission ision Values >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Our Mission The Co-operators: financial security for Canadians
June 2014 An RBC Social Finance White Paper Financing Social Good: A Primer on Impact Investing in Canada Impact Investing in Canada 2 This report was prepared by RBC in collaboration with the MaRS Centre
Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain Prepared for The Kaiser Family Foundation by: The Health Strategies Consultancy LLC March 2005 Table of Contents I. Executive
Guide for Investors in Private Health Care in Emerging Markets IFC Guide for Investors in Private Health Care in Emerging Markets i Contents Foreword 3 Acknowledgements 4 About IFC 5 Acronyms 7 Introduction
Annual Reports and Financial Statements 2006 Inspiring discovery Reed Elsevier is a world leading provider of Science and Medical, Legal, Education and Business information and workflow solutions. We create
OUR MISSION,VISION, STRATEGIC GOALS, AND OBJECTIVES 1 STRATEGIC GOAL 2 Our Mission,Vision,Strategic Goals, and Objectives Mission Statement The Department of Commerce creates the conditions for economic
Making the UK the best place to invest 2 Table of contents Our vision for the UK 3 Executive summary 4 Nine key facts why government must take action 5 The investment challenge 6 Introduction: investment
Annual Reports and Financial Statements www.reedelsevier.com _Reed_Covers_Final.indd 18 Annual Reports and Financial Statements 11/03/2013 08:45 Reed Elsevier is a world leading provider of professional
Invest More, Innovate More, Trade More, Learn More: The Way Ahead for Nova Scotia Donald J. Savoie July 2010 Contents Invest More, Innovate More, Trade More, Learn More: The Way Ahead for Nova Scotia...
Healthcare: Reform or ration April 2013 with support from: Healthcare: Reform or ration April 2013 About this publication CEDA 2013 ISBN: 0 85801 286 3 The views expressed in this document are those of
Chapter 2 OVERVIEW OF PRESCRIPTION DRUG BENEFITS IN MANAGED CARE ROBERT P. NAVARRO AND RUSTY HAILEY INTRODUCTION A prescription drug program is a vital component of comprehensive healthcare benefits offered
The National Cloud Computing Strategy May 2013 dbcde.gov.au/cloud nbn.gov.au Commonwealth of Australia 2013 The material in this paper is licensed under a Creative Commons Attribution 3.0 Australia license,